These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 26344764)

  • 1. Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects.
    Kholodenko BN
    Cell Rep; 2015 Sep; 12(11):1939-49. PubMed ID: 26344764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF.
    Gunderwala AY; Nimbvikar AA; Cope NJ; Li Z; Wang Z
    ACS Chem Biol; 2019 Jul; 14(7):1471-1480. PubMed ID: 31243962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular dynamics simulations and modelling of the residue interaction networks in the BRAF kinase complexes with small molecule inhibitors: probing the allosteric effects of ligand-induced kinase dimerization and paradoxical activation.
    Verkhivker GM
    Mol Biosyst; 2016 Oct; 12(10):3146-65. PubMed ID: 27481329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analyses of the oncogenic BRAF
    Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
    J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
    Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways.
    Tse A; Verkhivker GM
    PLoS One; 2016; 11(11):e0166583. PubMed ID: 27861609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.
    Karoulia Z; Wu Y; Ahmed TA; Xin Q; Bollard J; Krepler C; Wu X; Zhang C; Bollag G; Herlyn M; Fagin JA; Lujambio A; Gavathiotis E; Poulikakos PI
    Cancer Cell; 2016 Sep; 30(3):485-498. PubMed ID: 27523909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
    Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
    Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric coupling asymmetry mediates paradoxical activation of BRAF by type II inhibitors.
    Rasmussen DM; Semonis MM; Greene JT; Muretta JM; Thompson AR; Toledo Ramos S; Thomas DD; Pomerantz WCK; Freedman TS; Levinson NM
    Elife; 2024 May; 13():. PubMed ID: 38742856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stabilization of a closed kinase conformation induces RAF dimerization.
    Cancer Discov; 2013 Jul; 3(7):715. PubMed ID: 23847340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers.
    Grasso M; Estrada MA; Berrios KN; Winkler JD; Marmorstein R
    J Med Chem; 2018 Jun; 61(11):5034-5046. PubMed ID: 29727562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
    Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
    Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric activation of functionally asymmetric RAF kinase dimers.
    Hu J; Stites EC; Yu H; Germino EA; Meharena HS; Stork PJS; Kornev AP; Taylor SS; Shaw AS
    Cell; 2013 Aug; 154(5):1036-1046. PubMed ID: 23993095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation.
    Thevakumaran N; Lavoie H; Critton DA; Tebben A; Marinier A; Sicheri F; Therrien M
    Nat Struct Mol Biol; 2015 Jan; 22(1):37-43. PubMed ID: 25437913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
    Gowrishankar K; Snoyman S; Pupo GM; Becker TM; Kefford RF; Rizos H
    J Invest Dermatol; 2012 Jul; 132(7):1850-9. PubMed ID: 22437314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation and role of Raf-1/B-Raf heterodimerization.
    Rushworth LK; Hindley AD; O'Neill E; Kolch W
    Mol Cell Biol; 2006 Mar; 26(6):2262-72. PubMed ID: 16508002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers.
    Yadav V; Chen SH; Yue YG; Buchanan S; Beckmann RP; Peng SB
    Pharmacol Ther; 2015 May; 149():139-49. PubMed ID: 25550229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.